Navigation Links
Korean Food and Drug Administration Approval for ActiPatch Achieved
Date:10/16/2007

FREDERICK, Md., Oct. 16 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL), announced today that the by the Korean Food and Drug Administration has cleared ActiPatch for sale in Korea.

"We have been working closely with our distributor, YoungKwangSa Co., Ltd., to achieve the approval of the Korean F.D.A. Having worked so diligently to obtain the approvals, we are confident that YoungKwangSa is now poised to successfully launch ActiPatch in the Korean market. We expect to ship the initial stock order within the next 15 days," said Andrew Whelan, President of BioElectronics Corporation.

Marshal Nam of YoungKwangSa said "We are pleased to have achieved the clearance from the Korean FDA to begin importing the ActiPatch device. It was a long process and we worked cooperatively with BioElectronics Corporation to obtain the necessary approvals. We are excited to represent ActiPatch in Korea and expect to have a strong business relationship with BioElectronics Corporation for many years."

About YoungKwangSa Co., Ltd.:

Founded in 1971, YoungKwangSa has provided medical professionals in Korea with the most state-of-the art medical devices available. To learn more about YoungKwangSa please visit http://www.actipatch.co.kr.

About BioElectronics:

BioElectronics Corporation is the maker of ActiPatch. ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.

For more information visit http://www.bioelectronicscorp.com

Safe Harbor Statement:

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Brady Corp. acquires Korean counterpart
2. Third Wave seeks approval of Cystic Fibrosis test
3. Kyron wins FDA approval for brain imaging technology
4. SGI receives court approval for bankruptcy motions
5. FDA programs encourage and expedite drug development and approval
6. UW-Stevens Point Professor Receives Patent Approval For New Technology
7. High-Efficiency Transfections Achieved with New Low-Toxicity Reagent
8. 140-Fold Increase of Protein Achieved in Pichia Fermentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... ... Personal eye wash is a basic first aid supply for any work environment, but most ... you rinse first if a dangerous substance enters both eyes? It’s one less decision, and ... unique dual eye piece. , “Whether its dirt and debris, or an acid or alkali, ...
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... implantation and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... and maternal age to IVF success. , After comparing the results from the ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
Breaking Biology News(10 mins):